Clinical Trial

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Study acronym: CLARITY
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) fatigue scale ratings, independently from other prognostic factors for OS in multiple myeloma (MM), including the clinically-based prognostic frailty score.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-06-14; most recent amendment 2025-06-09.
Status change: Recruiting → Active, Not Recruiting 2025-06-09
Status change: Active, Not Recruiting → Recruiting 2022-06-22
Status change: Recruiting → Active, Not Recruiting 2019-03-19
Status change: Not Yet Recruiting → Recruiting 2017-12-15
Trial Details
NCT Number NCT03190525
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Multiple Myeloma
Enrollment 530 participants
Start Date 2017-11-13
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-12